Location expands company’s pharmacovigilance, regulatory affairs services
PharmaLex Group, a specialized services source for the pharma, biotech, and medtech industries, is opening a new branch in Beijing, China.
The newly established PharmaLex Beijing team, featuring personnel joining from Bayer China, will be offering the full PharmaLex package for pharmacovigilance, regulatory affairs, development consulting, and quality management to global clients bringing products to the China market. PharmaLex China will also be the local contact point for Chinese-based biopharma companies that are developing pharmaceuticals or medical devices with a goal of entering the European or US markets.
Pharmalex is also preparing to open a second China office in Jinan.
“APAC [Asia-Pacific], and China in particular, is a strategic focus region for the pharmaceutical industry, both from a global perspective and in terms of the development of China-based companies,” comments Dr. Thomas Dobmeyer, PharmaLex CEO. “Onboarding the China team to the PharmaLex organization underscores our commitment to employing the right expertise in all our global offices. We are honored to welcome the team of highly experienced China personnel, and together, develop our skills and capabilities with these valued colleagues while offering them career and expertise development.”
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
Is Compounding the Answer to the Semaglutide Shortage? Experts Weigh In
October 30th 2024In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications.